SubHero Banner

Rylaze(asparaginase erwinia chrysanthemi [recombinant]¬rywn) – New orphan drug approval

June 30, 2021 - The FDA announced the approval of Jazz Pharmaceuticals’ Rylaze (asparaginase erwinia chrysanthemi [recombinant]¬rywn), as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.

Download PDF